Drugs Fut 2021, 46(2): 129
ISSN 0377-8282
Copyright 2021 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.2.3176879

TNP-2092. RNA polymerase (bacterial) inhibitor, DNA gyrase (bacterial) inhibitor, DNA topoisomerase IV (bacterial) inhibitor, Treatment of medical device-associated bacterial biofilm infections

Takare, R., Dasgupta, A., Chopra, S.

The unrelenting rise of drug-resistant infections including those caused by biofilm-forming bacterial pathogens negatively impacts morbidity and mortality worldwide and demands the urgent discovery and development of novel therapeutics. In this context, TNP-2092 is a multitargeting drug conjugate that is designed to exert antibacterial activity by inhibiting 3 essential bacterial targets, such as RNA polymerase, DNA gyrase and topoisomerase IV, and consists of rifampicin and a quinolizinone-derived pharmacophore (ABT-719). The hybrid demonstrated more potent activity compared with both parent drugs individually and has a low propensity for resistance development since it targets 3 essential bacterial enzymes. The U.S. Food and Drug Administration (FDA) has granted fast track and orphan drug designations to TNP-2092 powder for intravenous injection for the treatment of prosthetic joint infections. TNP-2092 has also received a qualified infectious disease product designation in the U.S.

特别声明：本文为转载内容，所涉字体、图片等素材版权归原作者所有。本次发布仅供学习交流之用，不涉及任何商业用途。Link to the article: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3176879&p_IsPs=N.‍

关于丹诺医药

丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。凭借自主开发的多靶点偶联分子技术，丹诺致力于为患者提供最佳治疗方案，以克服传统治疗的局限性并改善患者预后。截至2026年1月24日，丹诺已建立一条由七项创新项目组成的管线，包括两项核心产品，即：利福特尼唑(TNP-2198)，一款新分子实体（“NME”）候选药物在中国及美国作为三联疗法的一部分与阿莫西林和PPI联合使用治疗幽门螺杆菌（“幽门螺杆菌”）感染，亦在中国作为单药疗法用于治疗细菌性阴道病及艰难梭菌感染；及利福喹酮（TNP-2092注射剂），一款三靶点治疗植入体相关细菌感染（如急性细菌性皮肤及皮肤结构感染（“ABSSSI”）及人工关节感染（“PJI”）以及在中国及美国治疗左心室辅助装置感染（“LVADI”）及中心静脉导管相关血流感染（“CRBSI”））的候选药物。

如需更多信息，请访问：www.tennortherapeutics.com